SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Pharmaids Pharmaceuticals Ltd

BSE: 524572 NSE: ISIN: INE117D01018
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Pharmaids Pharmaceuticals Ltd belong to?
Pharmaids Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Pharmaids Pharmaceuticals Ltd a good quality company?
Pharmaids Pharmaceuticals Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Pharmaids Pharmaceuticals Ltd undervalued or overvalued?
Pharmaids Pharmaceuticals Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Pharmaids Pharmaceuticals Ltd a good buy now?
Pharmaids Pharmaceuticals Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd revenue growth is 7,700% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.2 Gross Profit margin of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is -358.3% for FY-2025 , which is below its 5 year median of 0% , indicating decreasing margins.
Q.3 Operating Profit Margin of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -310% for FY-2025 , which is below its 5 year median of 0% indicating decreasing margins.
Q.4 Net Profit Margin of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Net Profit Margin is -310.96% for FY-2025 , is below with its 5 year median of -%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin -358.3 -
Operating Profit Margin -310 -
Net Profit Margin -310.96 -
Q.5 Return on Asset of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Return on Asset is -7.48%, which is in line with its 5 year historical median of -7.48%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Return on equity is -10.8% for FY-2025 , which is below its historical median of -10.64%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Return on capital employed is -6.89% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Cash conversion cycle is 655 days, above its historical median of 12 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.02 0.02
ROE -10.8 -10.64
ROCE -6.89 -6.89
Cash Conversion Cycle 655 days 12 days
Q.9 Debt to Equity ratio of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Debt-to-Equity ratio is 0.62 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Pharmaids Pharmaceuticals Ltd?
Pharmaids Pharmaceuticals Ltd Debt to cash flow from operations is -5.1 , which is at a unhealthy level, indicating the business is not able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Pharmaids Pharmaceuticals Ltd?
Promoters hold 32.99% of the Pharmaids Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Pharmaids Pharmaceuticals Ltd vs industry peers?
Pharmaids Pharmaceuticals Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 2.3 137.1
Gross Profit -7.2 15.1
Operating Profit -7 16
Net Profit -7 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.02 0.8
ROE -10.8 8.91
ROCE -6.89 11.59
Cash Conversion Cycle (days) 654.89 76

Valuation & price assessment

Q.1 Stock return of Pharmaids Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 19% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 19% 21.2% 16.1% -53%
Q.3 Valuation ratios of Pharmaids Pharmaceuticals Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 39.58 40.28
Price to Book 1.99 1.42 2.77
Price to Sales 13.5 5.49 2.65
EV to EBITDA -10.39 172.08 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Pfizer
6. Wockhardt
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Acutaas Chemicals
10. Piramal Pharma
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×